Indian drugmaker Biocon aims to be the world's top insulin supplier within five years, capitalising on growing demand as major pharmaceutic...

Nomura has raised its target price on Adani Ports and Special Economic Zone to Rs 2,080 from Rs 1,850, while retaining its Buy rating. The ...

Indian stocks are poised for a favorable period. Falling crude oil prices and a strengthening rupee offer support. Macroeconomic conditions...

Global drug companies are boosting U.S. production and stockpiling medicines. This is a response to potential tariffs on branded drugs. Com...

Brokerages remain selective on India's energy sector, favouring companies with strong growth drivers and attractive valuations. Morgan Stan...

On Thursday evening, US President Trump said he would “hit Iran hard tonight”. Then, as the world waited with bated breath, came the announ...

We are in a phase in the US-Israel-Iran war where statements are made, then retracted. And, in a matter of just 48 hours, they are made all...

Our technical analysts identify select stocks every trading day that may gain momentum even in volatile markets. Here are the technical cal...

India's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...

India is increasingly becoming a long-term structural investment destination rather than a short-term strategic bet. Global capital is movi...

India's drug pricing authority has approved a 50% price hike for essential anti-cancer drugs carboplatin and cisplatin. This decision follo...

India's government is taking emergency steps to ensure cancer patients get vital drugs. Cisplatin and carboplatin, crucial chemotherapy age...

Union Minister Piyush Goyal said he held a meeting with Janet Truncale, Global Chair and CEO of EY, to discuss India's growing role in glob...

Private equity firm BC Investments IV sold a Rs 612 crore stake in Emcure Pharmaceuticals to Kotak Mahindra Mutual Fund at Rs 1,700 per sha...

A promoter entity of Ajanta Pharma sold shares worth over Rs 1,024 crore through a block deal, with Kotak Mahindra Mutual Fund and Aditya B...

The latest escalation in the US-Iran war means that crude oil price is back as a risk for India. Although we are in a market already strugg...

There was a time when the Indian pharma story in the US was almost entirely about inspection risk. The US FDA would inspect a plant, a warn...